Multiple Myeloma Clinical Trial
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
The purpose of this study is to test the safety and efficacy of Selinexor and Dexamethasone and see what effects it has on AL amyloidosis.
Diagnosis of primary AL amyloidosis
Relapsed and/or refractory AL amyloidosis
Male or female patients 18 years or older
Able to give voluntary written consent
Eastern Cooperative Oncology Group performance status and/or other performance status 0, 1, or 2.
Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet count ≥ 75,000/mm3.
Total bilirubin ≤ 1.5 × the upper limit of the normal range (ULN).
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN.
Calculated creatinine clearance ≥ 30 mL/min
Clinically overt myeloma
Prior exposure to Selinexor
Clinically significant cardiac disease
Severe obstructive airway disease
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Planned high-dose chemotherapy and autologous stem cell transplantation within 6, 28-day treatment cycles after starting on treatment
Failure to have fully recovered (ie, ≤ Grade 1 toxicity) from the reversible effects of prior chemotherapy.
Major surgery within 14 days before enrollment.
Radiotherapy within 14 days before enrollment.
Infection requiring systemic intravenous antibiotic therapy or other serious infection within 14 days before study enrollment. Systemic treatment, within 14 days before the first dose, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, see Appendix 11.7), or use of Ginkgo biloba or St. John's wort.
Positive for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C
Serious medical or psychiatric illness
GI disease or GI procedure that could interfere with the oral absorption or tolerance including difficulty swallowing
Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
Participation in another clinical trials involving investigational agents within 30 days of starting this trial
Peripheral neuropathy (grade 2 with pain or grade 3 or higher).
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10065, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.